Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Acurx Pharmaceuticals, Inc. (ACXP)
|
Add to portfolio |
|
|
|
| Price: |
$4.74
| | Metrics |
| OS: |
13.0
|
M
| |
-212
|
% ROE
|
| Market cap: |
$61.6
|
M
| |
|
|
|
Net cash:
|
$9.15
|
M
| |
$0.70
|
per share
|
|
EV:
|
$52.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 |
| Revenues | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 |
| Research and development | 4.8 | 2.0 | 2.2 |
| General and administrative | 7.3 | 10.8 | 2.4 |
| EBIT | 0.0 | -12.7 | 0.0 |
| Pre-tax income | -12.1 | -12.7 | -4.6 |
| Income taxes | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% |
| Net income | -12.1 | -12.7 | -4.6 |
| |
| Diluted EPS | ($1.12) | ($1.49) | ($0.74) |
| Shares outstanding (diluted) | 10.8 | 8.5 | 6.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|